Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Accumulated Expenses (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Accumulated Expenses for 7 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 30.57% to $2.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 30.57% increase, with the full-year FY2024 number at $1.0 million, down 33.18% from a year prior.
  • Accumulated Expenses was $2.7 million for Q3 2025 at Vivos Therapeutics, up from $2.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $3.2 million in Q1 2022 to a low of $724000.0 in Q1 2025.
  • A 5-year average of $1.9 million and a median of $1.9 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 178.34% in 2021, then tumbled 70.64% in 2025.
  • Vivos Therapeutics' Accumulated Expenses stood at $2.9 million in 2021, then plummeted by 32.98% to $1.9 million in 2022, then fell by 21.65% to $1.5 million in 2023, then tumbled by 33.18% to $1.0 million in 2024, then surged by 167.93% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Accumulated Expenses are $2.7 million (Q3 2025), $2.3 million (Q2 2025), and $724000.0 (Q1 2025).